Eligo Bioscience reels in $20 mln Series A

Paris-based Eligo Bioscience, a microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured $20 million in Series A financing. The investors included Khosla Ventures and Seventure Partners.

ManagersNorth AmericaUSHealthcareBriefs